GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative

The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies

Charsire's new drug aims to capture dementia treatment market

Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease

C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership

Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Chennai's VS Hospitals introduce cutting-edge brain therapy with TMS

TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders

Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

The company is excluding data from the affected sites to maintain the study's integrity

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Ingenus Pharma launches first FDA-approved generic version of Premarin

Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature